Volume : 09, Issue : 05, May – 2022
Title:
61.REVIEW: DIFFERENT BENEFITS OF STREPTOMYCIN AND ITS MECHANISM OF ACTION
Authors :
Mohammed Ali Alshamrani, Naif Suliman Almahyawi, Doaa Omar Asraf, Khalid Abdullah AlHarbi, Bader Hadi Ali Alyami, ESSA MOHAMMED ALLBDI, Rezan Saeed Al amoudi, Ahmad Hassan Alomari, Majed Mnawer Almutery, Abdulrhman Munawer Almutairi
Abstract :
Streptomycin was the first aminoglycoside antibiotic discovered, derived from the bacteria Streptomyces griseus. It is now mostly used as part of a multi-drug regimen to treat pulmonary tuberculosis. It also exhibits efficacy against a variety of aerobic gram-negative bacteria. We scan electronic databases for relevant papers on the subject that were published up to 2022. Streptomycin is now mostly used as part of a multi-drug regimen for treating pulmonary tuberculosis. It has extra efficacy against certain aerobic gram-negative bacteria and is still the favored treatment for zoonotic illnesses including plague and tularemia. Although streptomycin has traditionally been the drug of choice treating these infections, gentamicin is now routinely utilized due to its increased availability and data indicating equivalent efficacy to streptomycin.
Cite This Article:
Please cite this article in press Mohammed Ali Alshamrani et al, Review: Different Benefits Of Streptomycin And Its Mechanism Of Action, Indo Am. J. P. Sci, 2022; 09 (05).
Number of Downloads : 10
References:
1. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy. 2001 Sep;21(9):1037-45.
2. Daniel TM. Selman Abraham Waksman and the discovery of streptomycin. Int J Tuberc Lung Dis. 2005 Feb;9(2):120-2.
3. Ball AP, Gray JA, Murdoch JM. Antibacterial Drugs today: II. Drugs. 1975;10(2):81-111.
4. Camba SA, Alterthum F, De Carvalho Lima LP. Some evidences for the hypothesis of active transport of streptomycin in Pseudomonas aeruginosa. Chemotherapy. 1976;22(6):341-5.
5. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009 Feb;10(3):381-401.
6. Chan J, Flynn J. 2004. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110:2–12
7. Dooley KE, Chaisson RE. 2009. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9:737–746.
8. Vianna JF, S Bezerra K, I N Oliveira J, Albuquerque EL, Fulco UL. Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits. Phys Chem Chem Phys. 2019 Sep 21;21(35):19192-19200.
9. Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics? Arch Dis Child Educ Pract Ed. 2017 Apr;102(2):89-93.
10. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in U.S. and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents 43: 328–334.
11. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother 59: 3263–3270.
12. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. 2012. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 47: 44–52.
13. Stubbings W, Bostock J, Ingham E, Chopra I. 2006. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother 58: 444–448.
14. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother. 2012 Nov;56(11):5782-9.
15. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. 2013. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41: 580–637.
17. Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y. 2004. Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother 48: 491–496.
18. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45: 753–760.
19. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-López F, et al. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70: 905–913.